TScan Therapeutics (TCRX) Operating Income (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Operating Income of -$29.1 million for Q1 2026, up 19.62% year-over-year from -$24.4 million in Q1 2025, and down 22.14% quarter-over-quarter from -$23.9 million in Q4 2025.
TScan Therapeutics (TCRX) Operating Income (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Operating Income for 7 consecutive years, with -$29.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 19.62% year-over-year to -$29.1 million; the TTM figure through Mar 2026 stood at -$128.7 million (up 7.87% YoY), while the FY2025 annual figure was -$135.8 million, down 0.74% from the prior year.
- Operating Income slipped to -$29.1 million in Q1 2026 per TCRX's latest filing, from -$23.9 million in the prior quarter.
- Across five years, Operating Income topped out at -$15.2 million in Q2 2022 and bottomed at -$38.7 million in Q2 2025.
- Historically, Operating Income has averaged -$27.1 million across 5 years, with a median of -$24.7 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income sank 104.13% — and 2025, when it jumped 35.01%.
- TScan Therapeutics' Operating Income stood at -$18.6 million in 2022, then retreated by 14.52% to -$21.4 million in 2023, then tumbled by 71.9% to -$36.7 million in 2024, then surged by 35.01% to -$23.9 million in 2025, then decreased by 22.14% to -$29.1 million in 2026.
- Business Quant data shows TCRX's Operating Income at -$29.1 million in Q1 2026, -$23.9 million in Q4 2025, and -$37.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -30.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.49 Mn |
| Mar 31, 2026 | -29.14 Mn |
| Dec 31, 2025 | -23.86 Mn |
| Sep 30, 2025 | -37.05 Mn |
| Jun 30, 2025 | -38.65 Mn |
| Mar 31, 2025 | -36.25 Mn |
| Dec 31, 2024 | -36.71 Mn |
| Sep 30, 2024 | -32.62 Mn |
| Jun 30, 2024 | -34.11 Mn |
| Mar 31, 2024 | -31.37 Mn |
| Dec 31, 2023 | -21.36 Mn |
| Sep 30, 2023 | -24.75 Mn |
| Jun 30, 2023 | -24.61 Mn |
| Mar 31, 2023 | -22.74 Mn |
| Dec 31, 2022 | -18.65 Mn |
| Sep 30, 2022 | -16.58 Mn |
| Jun 30, 2022 | -15.25 Mn |
| Mar 31, 2022 | -16.16 Mn |
| Dec 31, 2021 | -14.20 Mn |
| Sep 30, 2021 | -15.84 Mn |